BioSpace News Archive

Genetown

Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting

Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoing Phase 1 dose-escalation trial in relapsed or refractory NHL

December 7, 2019
·
7 min read
MaaT Pharma Announces the Presentation of Positive Data with Its Lead Microbiome Biotherapeutic in Intestinal-Predominant Acute Graft-versus-Host-Disease at the ASH 2019 Annual Meeting

MaaT Pharma’s full-ecosystem microbiota biotherapeutic provided positive impact with satisfactory safety profile in eight patients with advanced stages of GI aGvHD

December 7, 2019
·
6 min read
Biotech Bay

ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, announced new results from the hematological portion of the ALX148 Phase 1 program at the 2019 ASH Annual Meeting.

December 7, 2019
·
4 min read
Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019

Oncopeptides AB will present follow-up data from the pivotal Phase 2 HORIZON study at the ASH Annual Meeting 2019.

December 7, 2019
·
5 min read
Drug Development

Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma

NDA Submission for Accelerated Approval of Tazemetostat for Patients with Relapsed or Refractory Follicular Lymphoma on Track for December 2019

December 7, 2019
·
8 min read
Aptose Presents Highlights From Corporate Event At ASH

Aptose Biosciences Inc. released highlights from a corporate event and clinical update held at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, FL.

December 7, 2019
·
7 min read
Biotech Beach

Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting

Study results showed EPIDIOLEX significantly reduced difficult-to-treat seizures associated with TSC and improved overall patient condition as reported by caregivers

December 7, 2019
·
8 min read
Drug Development

Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment

47 Percent of Refractory Large B-cell Lymphoma Patients in ZUMA-1 Pivotal Phase 2 Cohorts Were Alive Three Years after a Single Infusion of Yescarta

December 7, 2019
·
12 min read
Pharm Country

Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study

Data from the pivotal liso-cel TRANSCEND NHL 001 study demonstrate patients with relapsed/refractory large B-cell lymphomas experienced high rate of durable responses

December 7, 2019
·
9 min read
Genetown

First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers

Magenta Therapeutics announced that new results from its MGTA-145 stem cell mobilization program were presented at the 61st Annual Meeting of the American Society of Hematology.

December 7, 2019
·
7 min read